Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
    Meeting Abstract

    Zalcberg, J. R.; Heinrich, M.; George, S.; Bauer, S.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I
    Meeting Abstract

    Janku, F.; Chi, P.; Heinrich, M.; von Mehren, M.; Jones, R. L.; Ganjoo, K.; Trent, J.; Gelderblom, H.; Abdul Razak, A.; Gordon, M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors
    Meeting Abstract

    Morschhauser, F.; McKay, P.; Salles, G.; Stacchiotti, S.; Schwartz, G. K.; Tilly, H.; Zauderer, M. G.; Fennell, D. A.; Jones, R. L.; Schöffski, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Real-world treatment patterns and effectiveness of liposomal irinotecan in a NAPOLI1-based regimen among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): A multi-academic center chart review
    Meeting Abstract

    Yu, K. H.; Hendifar, A.; Alese, O.; Draper, A.; Abdelrahim, M.; Burns, E.; Khan, G.; Cockrum, P.; Bhak, R.; Nguyen, C.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Quality of life in cancer patients treated with immune checkpoint inhibitors: A meta-analysis
    Meeting Abstract

    Gonzalez, B. D.; Eisel, S. L.; Bowles, K. E.; Hoogland, A. I.; James, B. W.; Small, B. J.; Sharpe, S.; Hyland, K. A.; Bulls, H. W.; Christy, S. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma
    Meeting Abstract

    Ludwig, J. A.; Federman, N.; Anderson, P.; Macy, M. E.; Davis, L. E.; Riedel, R. F.; Muscal, J. A.; Daw, N. C.; Ratan, R.; Toretsky, J.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Preliminary safety and activity of CLN-081 in NSCLC with EGFR exon 20 insertion mutations (Ins20)
    Meeting Abstract

    Piotrowska, Z.; Nguyen, D.; Koczywas, M.; Tchekmedyian, N.; Clancy, M. S.; Witter, D.; Page, A.; Zawel, L.; Yu, H. A.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in patients (pts) with NSCLC harboring MET exon 14 skipping (METex14) treated with tepotinib
    Meeting Abstract

    Garassino, M. C.; Le, X.; Kowalski, D. M.; Migliorino, M. R.; Senellart, H.; Fuentes Pradera, J.; Walling, R.; Kato, T.; Thomas, M.; Smit, E. F.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • LIBRETTO-431: Selpercatinib in treatment (Tx)-naive patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Loong, H. H. F.; Goto, K.; Elamin, Y. Y.; Solomon, B.; Santini, F. C.; Soldatenkova, V.; Sashegyi, A.; Bence Lin, A.; Lin, B. K.; Wolf, J.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A phase Ib/II, multicenter, open-label, dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd; DS8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03)
    Meeting Abstract

    Janjigian, Y. Y.; Viglianti, N.; Liu, F.; Mendoza-Naranjo, A.; Puvvada, S.
    Annals of Oncology (2020)

    Fulltext@MSK | Save